APPENDIX I:

CLAIM AMENDMENTS:

Cancel Claim 5, and amend Claim 1, as indicated in the following listing of the claims:

 (currently amended) A process for preparing chiral imidazolidin-2-ones of the general formula I

in which

- R¹ is C₁-C₈-alkyl, cyclohexyl, phenyl, a C₁-C₆-alkyl-, halo-, nitro-, C₁-C₆-alkoxy-, C₁-C₆-alkylmercapto- or CF₃-substituted phenyl radical, naphthyl or a C₁-C₆-alkyl-, halo-, nitro-, C₁-C₆-alkoxy- or CF₃-substituted naphthyl radical,
- R^2 is $C_1-C_8-alkyl,\ C_2-C_8-alkenyl,\ cyclohexyl,\ phenyl or a phenyl- <math display="block">C_1-C_6-alkyl\ radical\ which\ may\ be\ substituted\ by\ a\ nitro,$ $C_1-C_6-alkoxy,\ methylenedioxy\ or\ CF_3\ radical,\ and$
- R^3 is $C_1-C_{12}-alkyl,\ C_2-C_8-alkenyl,\ cyclohexyl,\ phenyl or a <math display="inline">C_1-C_6-alkyl-$, halo-, nitro-, $C_1-C_6-alkoxy-$, methylenedioxy-, dial-kylamino- or $CF_3-substituted$ phenyl radical,

by reacting a compound of the formula II or the salt thereof

in which R^1 , R^2 and R^3 have the abovementioned meaning,

with urea in the presence of an ammonium salt, wherein the reaction is carried out in the presence of a polar organic solvent and the reaction takes place in solution at temperatures of from 170 to 1905C 190°C, and wherein the reaction is carried out in the presence of proton donors, wherein an acid with a pKa of \leq 3 is used as proton donor.

- (original) A process as claimed in claim 1, wherein an aprotic solvent is used.
- (previously presented) A process as claimed in claim 1, wherein N-methylpyrrolidone is employed as organic solvent.

071001 - 3 -

- 4. (previously presented) A process as claimed in claim 1, wherein R1 is phenvl and R2 and R3 are methvl.
- 5. (canceled)
- 6. (previously presented) A process as claimed in claim 1, wherein paratoluenesulfonic acid is employed as proton donor.
- 7. (previously presented) A process as claimed in claim 1, wherein sulfamic acid is employed as proton donor.
- 8. (previously presented) A process as claimed in claim 1, wherein the proton donor is employed in amounts of from 0.05 to 0.6 equivalent based on the compound of the formula II.
- 9. (previously presented) A process as claimed in claim 1, wherein (1S,2R)-ephedrine or a salt thereof is employed as compound of the formula II.
- 10. (previously presented) A process as claimed in claim 1, wherein (1R,2S)-ephedrine or a salt thereof is employed as compound of the formula II.

071001 - 4 -